🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Glenmark Pharmaceuticals Limited GLENMARK NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://glenmarkpharma.com
Company Profile ↓
₹2,311.60
+21.71% 1Y
Mkt Cap₹65,233.54 Cr
P/E47.92
P/B6.18
Div. Yield0.22%
52W High₹2,417.90
52W Low₹1,810.40
Book Value₹372.50
EPS (TTM)₹48.24

Company Overview

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 16.2%.

Consistent Profit Growth

Net profit has compounded at 66.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Healthy Margins

Operating margin of 23.9% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹16,711.40 Cr (+27.1% YoY); net profit ₹1,361.85 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +27.1%, earnings +30.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%, profit CAGR 66.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.49%
1 Year:27.12%

Compounded Profit Growth

5 Years:66.09%
1 Year:30.06%

Stock Price Performance

1 Year:+21.71%
6 Months:+14.58%
3 Months:+2.76%
1 Month:+7.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 83% of range
₹1,810.40 ₹2,417.90
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.87 · Neutral
Price Performance
1M+7.18%
3M+2.76%
6M+14.58%
1Y+21.71%
Valuation vs Sector

P/E of 47.92 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.5% over 5 years.
  • Profit CAGR of 66.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
47.92
Industry PE
39.97
Forward P/E
23.52
PEG Ratio
-
Book Value
₹372.50
Price to Book
6.18
P/S
3.82
EV/EBITDA
14.08
Dividend Yield
0.22%

Growth (CAGR)

Revenue 5Y
13.49%
Profit 5Y
66.09%
Revenue (YoY)
27.12%
Earnings (YoY)
30.06%

Profitability & Returns

ROCE
16.21%
ROE
12.96%
ROA
6.84%
Profit Margin
8.15%
Op Margin
23.93%
Gross Margin
71.59%
EPS (Latest Qtr)
₹10.68
EPS (TTM)
₹48.24

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
1.23
Current Ratio
1.77
Debt
₹593.53 Cr
Total Assets
₹19,907.88 Cr
Current Assets
₹11,299.71 Cr
Working Capital
₹4,923.28 Cr

Ownership

Promoter Holding
48.97%
Chg in Prom Hold
2.32%
FII / Inst Holding
27.23%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
₹65,233.54 Cr
Total Revenue (TTM)
₹16,711.40 Cr
EBITDA
₹2,766.95 Cr
Free Cash Flow
₹2,087.32 Cr
Operating Cash Flow
₹3,445.03 Cr
Shares Outstanding
₹28.22 Cr
Gross Margin
71.59%
Payout Ratio
10.36%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GLENMARK Glenmark Pharmaceuticals Limited NIFTY_MIDNSEPHARMA 2,311.60 47.92 ₹65,233.54 Cr 0.22% 16.21% 12.96% 13.49% 66.09%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 3,001.00 Cr3,036.00 Cr3,207.00 Cr2,507.00 Cr3,063.00 Cr3,244.00 Cr-3,388.00 Cr3,220.13 Cr3,059.33 Cr6,003.79 Cr3,888.00 Cr3,760.28 Cr
Cost of Revenue --------1,088.95 Cr1,015.58 Cr1,264.51 Cr1,295.10 Cr1,172.28 Cr
Gross Profit --------2,131.18 Cr2,043.76 Cr4,739.29 Cr2,592.90 Cr2,588.00 Cr
Operating Expenses 2,603.00 Cr2,599.00 Cr2,745.00 Cr2,715.00 Cr2,559.00 Cr2,656.00 Cr-2,787.00 Cr1,695.36 Cr1,593.16 Cr2,520.94 Cr1,877.59 Cr1,973.31 Cr
Operating Income 263.00 Cr295.00 Cr321.00 Cr-356.00 Cr353.00 Cr470.00 Cr-477.00 Cr435.82 Cr450.59 Cr2,218.35 Cr715.30 Cr614.69 Cr
EBITDA 398.00 Cr437.00 Cr462.00 Cr-209.00 Cr504.00 Cr588.00 Cr-600.00 Cr199.89 Cr283.73 Cr1,175.06 Cr729.88 Cr578.28 Cr
Interest Expense 109.00 Cr112.00 Cr121.00 Cr134.00 Cr149.00 Cr40.00 Cr-52.00 Cr66.71 Cr58.23 Cr66.46 Cr41.43 Cr42.60 Cr
Pretax Income -542.00 Cr151.00 Cr-6.00 Cr-403.00 Cr555.00 Cr462.00 Cr-456.00 Cr7.97 Cr95.58 Cr967.40 Cr534.00 Cr387.77 Cr
Tax Provision 140.92 Cr-21.14 Cr-59.82 Cr72.54 Cr1,770.45 Cr120.12 Cr-109.44 Cr3.59 Cr48.60 Cr356.97 Cr130.77 Cr86.45 Cr
Net Income -403.00 Cr173.00 Cr-62.00 Cr-331.00 Cr-1,214.00 Cr340.00 Cr-348.00 Cr4.65 Cr46.87 Cr610.35 Cr403.21 Cr301.41 Cr
Diluted EPS -15.185.31-2.90-12.45-43.1712.06-12.330.161.6621.6214.2810.68

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 6,563.00 Cr7,562.00 Cr9,079.00 Cr9,074.00 Cr9,865.00 Cr10,641.00 Cr10,944.00 Cr-11,431.94 Cr11,635.46 Cr13,145.84 Cr16,711.40 Cr
Cost of Revenue --------4,586.60 Cr4,879.04 Cr4,353.34 Cr4,747.46 Cr
Gross Profit --------6,845.33 Cr6,756.42 Cr8,792.49 Cr11,963.94 Cr
Operating Expenses 5,348.00 Cr6,125.00 Cr7,043.00 Cr7,457.00 Cr8,280.00 Cr8,942.00 Cr8,860.00 Cr-5,766.46 Cr6,125.34 Cr6,927.12 Cr7,965.00 Cr
Operating Income 914.00 Cr1,203.00 Cr1,773.00 Cr1,315.00 Cr1,260.00 Cr1,282.00 Cr1,640.00 Cr-1,078.87 Cr631.08 Cr1,865.37 Cr3,998.94 Cr
EBITDA 1,214.00 Cr1,437.00 Cr2,037.00 Cr1,617.00 Cr1,586.00 Cr1,699.00 Cr2,084.00 Cr-1,200.15 Cr1,183.27 Cr2,092.28 Cr2,766.95 Cr
Interest Expense 190.00 Cr179.00 Cr237.00 Cr286.00 Cr335.00 Cr377.00 Cr353.00 Cr-349.04 Cr515.97 Cr207.06 Cr208.72 Cr
Pretax Income 544.00 Cr1,044.00 Cr1,491.00 Cr1,119.00 Cr1,301.00 Cr1,096.00 Cr1,382.00 Cr-239.84 Cr36.49 Cr1,399.21 Cr1,984.75 Cr
Tax Provision 331.84 Cr302.76 Cr387.66 Cr313.32 Cr377.29 Cr317.84 Cr414.60 Cr-329.40 Cr1,867.35 Cr352.07 Cr622.79 Cr
Net Income 209.00 Cr743.00 Cr1,109.00 Cr804.00 Cr925.00 Cr776.00 Cr970.00 Cr-297.25 Cr-1,501.67 Cr1,047.10 Cr1,361.85 Cr
Diluted EPS 7.7226.3339.2928.4932.7827.5034.38-10.53-53.2237.1148.24

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 8,309.00 Cr10,193.00 Cr11,764.00 Cr12,595.00 Cr13,289.00 Cr14,668.00 Cr15,575.00 Cr-19,371.68 Cr14,358.62 Cr16,049.55 Cr19,907.88 Cr
Current Assets --------10,725.53 Cr7,428.08 Cr9,295.47 Cr11,299.71 Cr
Cash & Equivalents --------1,159.20 Cr1,658.27 Cr1,675.71 Cr1,174.71 Cr
Inventory --------2,373.62 Cr2,513.05 Cr3,028.53 Cr3,430.78 Cr
Receivables --------3,665.17 Cr1,858.41 Cr3,341.95 Cr4,963.35 Cr
Total Liabilities --------9,532.42 Cr6,511.08 Cr7,200.48 Cr9,396.08 Cr
Current Liabilities --------5,105.06 Cr5,818.59 Cr5,967.02 Cr6,376.43 Cr
Long Term Debt --------3,852.14 Cr0512.70 Cr0
Total Debt 3,800.00 Cr3,988.00 Cr4,724.00 Cr4,639.00 Cr4,449.00 Cr4,869.00 Cr4,986.00 Cr-4,607.88 Cr1,230.93 Cr2,472.67 Cr593.53 Cr
Total Equity 1,783.00 Cr3,629.00 Cr4,492.00 Cr5,163.00 Cr5,605.00 Cr6,070.00 Cr7,064.00 Cr-9,473.92 Cr7,847.93 Cr8,849.44 Cr10,512.11 Cr
Shares Outstanding --------28.22 Cr28.22 Cr28.22 Cr28.22 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 482.00 Cr345.00 Cr657.00 Cr1,648.00 Cr1,324.00 Cr1,392.00 Cr1,131.00 Cr-625.39 Cr-265.44 Cr-827.60 Cr3,445.03 Cr
Investing Cash Flow -712.00 Cr-950.00 Cr-1,001.00 Cr-1,003.00 Cr-883.00 Cr-774.00 Cr-662.00 Cr--528.49 Cr4,560.89 Cr2.09 Cr-1,283.23 Cr
Financing Cash Flow 199.00 Cr699.00 Cr543.00 Cr-468.00 Cr-739.00 Cr-445.00 Cr-442.00 Cr--77.46 Cr-3,906.13 Cr787.04 Cr-2,708.75 Cr
Capital Expenditure -538.00 Cr-889.00 Cr-733.00 Cr-1,023.00 Cr-612.00 Cr-776.00 Cr-675.00 Cr--607.76 Cr-898.38 Cr-750.72 Cr-1,357.71 Cr
Free Cash Flow -56.00 Cr-544.00 Cr-76.00 Cr625.00 Cr712.00 Cr616.00 Cr456.00 Cr-17.63 Cr-1,163.82 Cr-1,578.32 Cr2,087.32 Cr
Net Change in Cash -31.00 Cr93.00 Cr199.00 Cr177.00 Cr-297.00 Cr174.00 Cr28.00 Cr-19.45 Cr389.32 Cr-38.46 Cr-546.95 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------59.9%58.1%66.9%71.6%
Operating Margin % 13.9%15.9%19.5%14.5%12.8%12.0%15.0%-9.4%5.4%14.2%23.9%
Net Margin % 3.2%9.8%12.2%8.9%9.4%7.3%8.9%-2.6%-12.9%8.0%8.1%
ROE % 11.7%20.5%24.7%15.6%16.5%12.8%13.7%-3.1%-19.1%11.8%13.0%
ROCE % --------7.6%7.4%18.5%29.6%

Shareholding Pattern

Insiders
48.97%
Institutions
27.23%
Public Float
53.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLENMARK

Google News Wed, 01 Jul 2026

Glenmark Pharma gets six procedural observations in US FDA inspection - ETLegalWorld.com

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNU1h5QXRxZDNOWXFwUXViMGk4emVfWnduYXhDeFhSVEM0Wm12NFByYUNPSkI3algzNXc2LXBLckg4OUtZcHlCZjY3dWQwMjhjcVRPdlRBSzhwdVFiOWVJd2ZuZUktTGxvX0IyN2FOdFNfcjZ0Z2VGU01WYmZVRVcxb01OeVA3d2I1aVB5eX…

Google News Mon, 06 Jul 2026

Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial - Business Standard

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOYmNjaXNzaGw5d2owRnIyek1lRFItNndQLXJnVVR2czhmMGZoSmgwcENoVnhzMmVOU3V6and3RjhreVUwbDBKTWRXdWFLX0lFMnBkNmE5YkVjcnI3NHltRWNsbDh3OEN5RG9fdnlwYlhHbURFZ3pkdmZpekVvUkFCeXEteHUwamI3enNCbV…

Google News hu, 02 Jul 2026

Glenmark Advances Phase 3 Cancer Trial; Shares Edge Higher - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPTG5sbTl2UWRXZm5YZEJIUFcxcnRobk55aTFlWDBqTUdrd1c2OEtaSHRqUUZLaGlpM1g1V2Zsd3B6RGdvUmRMZnVWTEVjcTlXamRPRGJTNVNXTEh3TlJDVURKQTloY3E1QzZnM08zZjdjbVlHMVd3LWxRRWdDX016b1Y5dDYyX1BmVnc?oc…

Google News hu, 25 Jun 2026

Glenmark Pharmaceuticals Limited Actuals & Estimates (NSE:GLENMARK) - TradingView

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxOcVdFQWNNaVF6QXlvWkFqYzVNNG55RDBjNWRGYjliYkhvWEMzR25zOW8wamstLWdMV1hIdk1mVlM2clQ2eFp4NzIyQ3hSUFFCMGg5TlFoTW0tVFNvVHU3UnRVMHExMXVCd0l6dV9TSDFCNDlBT2VyS1gxSUZ2MmcyZlZDbGEyelk?oc=5" …

Google News ue, 02 Jun 2026

Is Now The Time To Put Glenmark Pharmaceuticals (NSE:GLENMARK) On Your Watchlist? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxOcE1lTkVPOHZhWFN4QTdIQlFOT2VlTEg5SGJmVFl1eklfTHpGSzBwQlMxSlMzcURwYUZ4bGVtZGpTc29xSmJSelFaRU53WGZwN29KWlhfR3JCWHBhbXh4cGFKbTFhNThNSFdJeFZaYWs2U0FaOW5hZ29WQ2hyQV9qT2tja19icEE4RW9JbU…

Google News ue, 07 Jul 2026

Five Stocks To Buy: Adani Power, Glenmark Pharma, Tata Steel And More | July 7, 2026 - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQdmpKTURTZlhMSHRaS2dBSlNZT1RKLXpkeUR2QjhmU3V2TVdSTmlOQUZFcVhrLXB2Ulg3SWdiRm4teV9PdXliUVNLamQ3RHUyR0gtQzZBRkl3OTFoNXZKaU10LW9hWlh2RC1CV3FRX0tWQ0gxeGFwVHh6SXJYWVp4ako3WlhWUklRdHp0Z3…

GLENMARK — Frequently Asked Questions

What is the current share price of Glenmark Pharmaceuticals Limited (GLENMARK)?

As of 2026-07-15 09:52 IST, Glenmark Pharmaceuticals Limited (GLENMARK) trades at ₹2,311.60 on NSE. Its 52-week range is ₹1,810.40 to ₹2,417.90.

What is the market capitalisation of GLENMARK?

Glenmark Pharmaceuticals Limited (GLENMARK) has a market capitalisation of ₹65,233.54 Cr on NSE.

What is the P/E ratio of GLENMARK?

GLENMARK trades at a trailing price-to-earnings (P/E) ratio of 47.92. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.18.

Does GLENMARK pay a dividend?

Glenmark Pharmaceuticals Limited (GLENMARK) currently offers a dividend yield of 0.22%.

What is the return on equity (ROE) of GLENMARK?

GLENMARK has a return on equity (ROE) of 12.96%. Its return on capital employed (ROCE) is 16.21%.

Is GLENMARK a good stock to buy?

This page provides a data-driven analysis of Glenmark Pharmaceuticals Limited (GLENMARK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space